The links between joint damage and disability in rheumatoid arthritis.
about
Effects of glucocorticoids on radiological progression in rheumatoid arthritisDrugs in development: bisphosphonates and metalloproteinase inhibitorsThe value of sensitive imaging modalities in rheumatoid arthritisThe role of osteoprotegerin in arthritisAcute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.Smad-dependent mechanisms of inflammatory bone destructionImportance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts.Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis.Interpreting radiographic data in rheumatoid arthritis.Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial.[Measuring disease activity for rheumatoid arthritis]Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.Costs and outcomes for patients with rheumatoid arthritis treated with biological drugs in Sweden: a model based on registry data.Loss of Parkin reduces inflammatory arthritis by inhibiting p53 degradationEfficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterThe prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis.Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment.Relationship between time-integrated disease activity estimated by DAS28-CRP and radiographic progression of anatomical damage in patients with early rheumatoid arthritis.Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice.Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guideLong term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended studyInteractions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis.Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohortsOsteoclasts are essential for TNF-alpha-mediated joint destruction.Osteoclasts; culprits in inflammatory osteolysis.Repair of local bone erosions and reversal of systemic bone loss upon therapy with anti-tumor necrosis factor in combination with osteoprotegerin or parathyroid hormone in tumor necrosis factor-mediated arthritis.Macrophage migration inhibitory factor enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritisIndicators of walking speed in rheumatoid arthritis: relative influence of articular, psychosocial, and body composition characteristics.Predictors of radiographic joint damage in patients with early rheumatoid arthritis.What is the fate of erosions in early rheumatoid arthritis? Tracking individual lesions using x rays and magnetic resonance imaging over the first two years of disease.Long term efficacy and safety of cyclosporin versus parenteral gold in early rheumatoid arthritis: a three year study of radiographic progression, renal function, and arterial hypertension.MRI of the wrist in early rheumatoid arthritis can be used to predict functional outcome at 6 years.Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical descriptionPrediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP).A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial.The relation between cartilage biomarkers (C2C, C1,2C, CS846, and CPII) and the long-term outcome of rheumatoid arthritis patients within the CAMERA trial.Radiographic progression in rheumatoid arthritis: does it reflect outcome? Does it reflect treatment?Somatic antigens of tropical liver flukes ameliorate collagen-induced arthritis in wistar rats
P2860
Q24243070-98368930-A289-4A69-BC40-8EAE5A523EE3Q24795847-8F16F7A1-DCE8-4418-866C-EC47CBC938DEQ24797747-7AC9156C-8ECA-4E49-8E89-67ADC201E986Q24797889-2375466D-76EF-4E0F-BA3D-9B67476597DBQ24817087-1D95B200-7E9D-498F-BD07-86F402CD5185Q28066288-1F38F5B4-DA90-4226-9784-2197B5D2DD5DQ30313218-DBD0EC17-0D0D-458D-ACB8-FAC65D550FC9Q30739084-32F297AA-3E1D-47DC-9315-BEDF4FCCD94EQ30804224-84E8B574-A960-41D1-AB8E-003F5143B61EQ31019080-BE7B2047-6FD5-4F47-8881-85FDC6F78670Q33234551-59BC4327-05E6-4B03-8013-F2A975ABAE0BQ33424116-8960E67A-AD60-452F-BEDF-4EDCC046CDADQ33516150-D163D38D-BA54-46C6-BC69-77CCB328616CQ33555712-171CDCD0-79DF-4614-96A0-39D753D1503BQ33726924-F2AED343-B242-4B14-A3A7-D3F67FE3C443Q33896470-677DC7A5-28A8-439C-AF28-5F6F3CBE3D30Q33896725-B16CB8D5-0EAA-4388-A2FA-CD7CEA326450Q33915665-700BF450-244B-498C-8FC5-702022E8975DQ34071283-D9101E16-32D4-4B19-893A-A77F90466964Q34488033-23B1527A-F256-42D9-8B55-707B1FDBCADDQ34550160-9D1E91B8-D807-4F94-B1DC-CAF242D5C46EQ34562870-ED5E54EB-A85C-48E1-B1E5-E99D0881A2E8Q34758283-92498549-4510-4F30-8638-E469AD2A00CCQ34805081-44BEE2F6-1C2A-43B3-B479-5F77524F7BC1Q34826003-DC13C4DF-65FF-41B1-BD62-B5DDECCE65FBQ34896003-E4D92A58-4DED-42A6-A165-CD3982CA7702Q35083436-46CAABB3-85BF-4981-A811-EA40392C7150Q35092914-575FAD88-EEE9-4C74-BC6D-16A22F2E6A7DQ35108734-C0D3982D-B34A-4984-B43F-7F7EAB66D92DQ35549827-9BF57A30-C704-412C-90F5-864F3C03D2B1Q35550828-65FA4865-56F7-47D8-90F6-BC263735C7FFQ35551644-F6C7C8C0-994E-4CC2-9729-AA27BFF66AABQ35554101-F988F3BC-3A1D-4E31-B223-83084588CFFDQ35554244-220C1E48-7E95-433F-8F4F-C67CC73B4AE4Q35554533-A919A230-28E6-42A8-B260-1F5818F8DE98Q35554643-5A2EEC27-7D7F-4B20-A760-6739A585C3ACQ35555838-D537B57F-CB5E-41BF-8CC0-47EBF939C5F5Q35557805-5E192ACA-4057-4362-9377-0337A60CE082Q35579176-C054E08D-60FD-47B9-BFE6-648FA0A58505Q35620689-D5139D8D-F93D-42FE-8196-E8417F9DEE3B
P2860
The links between joint damage and disability in rheumatoid arthritis.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The links between joint damage and disability in rheumatoid arthritis.
@ast
The links between joint damage and disability in rheumatoid arthritis.
@en
type
label
The links between joint damage and disability in rheumatoid arthritis.
@ast
The links between joint damage and disability in rheumatoid arthritis.
@en
prefLabel
The links between joint damage and disability in rheumatoid arthritis.
@ast
The links between joint damage and disability in rheumatoid arthritis.
@en
P2093
P2860
P356
P1433
P1476
The links between joint damage and disability in rheumatoid arthritis.
@en
P2093
P2860
P304
P356
10.1093/RHEUMATOLOGY/39.2.122
P577
2000-02-01T00:00:00Z